Patient-reported outcomes (PRO) from a global phase 3 randomized controlled trial (RCT) of inotuzumab ozogamicin (InO) vs standard care (SC) for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 7027-7027
Author(s):  
Hagop M Kantarjian ◽  
Yun Su ◽  
Helen Bhattacharyya ◽  
Eric Yan ◽  
Mark Shapiro ◽  
...  
Sign in / Sign up

Export Citation Format

Share Document